Medication topics
Azathioprine articles covering immunomodulator treatment, safety monitoring, combination therapy, and IBD treatment decisions. Access context emphasizes approvals, coverage, affordability, availability, and policy decisions.
2 articles
Market reports can signal which drugs, companies, and biosimilars are becoming more available and may affect access and cost. Announcements about biosimilars could influence treatment affordability and prescribing...
This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.
